Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, Romeo M, Patti F, Chisari CG, Cocco E, Fenu G, Salemi G, Ragonese P, Inglese M, Cellerino M, Margari L, Comi G, Zaffaroni M, Ghezzi A; Italian MS registry. Baroncini D, et al. JAMA Neurol. 2021 Jun 1;78(6):726-735. doi: 10.1001/jamaneurol.2021.1008. JAMA Neurol. 2021. PMID: 33938921 Free PMC article.
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. Iaffaldano P, et al. Among authors: baroncini d. Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11. Brain. 2015. PMID: 26362907
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D'Amico E, Capobianco M, Bertolotto A, Gallo P, Margoni M, Miante S, Milani N, Amato MP, Righini I, Bellantonio P, Scandellari C, Costantino G, Scarpini E, Bergamaschi R, Mallucci G, Comi G, Ghezzi A. Baroncini D, et al. Among authors: d amico e. Mult Scler. 2019 Mar;25(3):399-407. doi: 10.1177/1352458518754364. Epub 2018 Jan 24. Mult Scler. 2019. PMID: 29363396
Impact of natural menopause on multiple sclerosis: a multicentre study.
Baroncini D, Annovazzi PO, De Rossi N, Mallucci G, Torri Clerici V, Tonietti S, Mantero V, Ferrò MT, Messina MJ, Barcella V, La Mantia L, Ronzoni M, Barrilà C, Clerici R, Susani EL, Fusco ML, Chiveri L, Abate L, Ferraro O, Capra R, Colombo E, Confalonieri P, Zaffaroni M. Baroncini D, et al. J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1201-1206. doi: 10.1136/jnnp-2019-320587. Epub 2019 Jun 12. J Neurol Neurosurg Psychiatry. 2019. PMID: 31189614
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Mult Scler. 2022 Jun;28(7):1034-1040. doi: 10.1177/13524585211035318. Epub 2021 Jul 30. Mult Scler. 2022. PMID: 34328824
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis.
Bergamaschi R, Ponzano M, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Pisoni E, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 study group. Bergamaschi R, et al. Eur J Neurol. 2022 Feb;29(2):535-542. doi: 10.1111/ene.15167. Epub 2021 Nov 15. Eur J Neurol. 2022. PMID: 34735749 Free PMC article.
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.
Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):e1105. doi: 10.1212/NXI.0000000000001105. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34753829 Free PMC article.
Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
Cosentino M, Zaffaroni M, Legnaro M, Bombelli R, Schembri L, Baroncini D, Bianchi A, Clerici R, Guidotti M, Banfi P, Bono G, Marino F. Cosentino M, et al. Among authors: baroncini d. J Neuroimmunol. 2016 Sep 15;298:82-9. doi: 10.1016/j.jneuroim.2016.07.008. Epub 2016 Jul 7. J Neuroimmunol. 2016. PMID: 27609280
55 results